These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38197142)

  • 1. A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials.
    Kus T; Cicin I
    Immunotherapy; 2024 Mar; 16(5):319-329. PubMed ID: 38197142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of RECIST 1.1 and iRECIST for Response Evaluation in Solid Tumours].
    Houdek Š; Büchler T; Kindlová E
    Klin Onkol; 2017; 30(Supplementum3):32-39. PubMed ID: 29239190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.
    Lai YC; Chang WC; Chen CB; Wang CL; Lin YF; Ho MM; Cheng CY; Huang PW; Hsu CW; Lin G
    Acta Radiol; 2020 Jul; 61(7):983-991. PubMed ID: 31739675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.
    Ahmed FS; Dercle L; Goldmacher GV; Yang H; Connors D; Tang Y; Karovic S; Zhao B; Carvajal RD; Robert C; Maitland ML; Oxnard GR; Schwartz LH
    Eur Radiol; 2021 Apr; 31(4):1853-1862. PubMed ID: 32995974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
    Seymour L; Bogaerts J; Perrone A; Ford R; Schwartz LH; Mandrekar S; Lin NU; Litière S; Dancey J; Chen A; Hodi FS; Therasse P; Hoekstra OS; Shankar LK; Wolchok JD; Ballinger M; Caramella C; de Vries EGE;
    Lancet Oncol; 2017 Mar; 18(3):e143-e152. PubMed ID: 28271869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
    BJU Int; 2021 Jan; 127(1):90-95. PubMed ID: 32662189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
    Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
    Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
    Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
    Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
    Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radiological response assessment of modern immunotherapy using iRECIST].
    Persigehl T; Poeppel TD; Sedlaczek O
    Radiologe; 2017 Oct; 57(10):826-833. PubMed ID: 28812098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.
    Huicochea Castellanos S; Pagano A; Plodkowski AJ; Girshman J; Hellmann MD; Rizvi H; Flynn J; Zheng J; Capanu M; Halpenny DF; Ginsberg MS
    Lung Cancer; 2021 Nov; 161():60-67. PubMed ID: 34536733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of RECIST and iRECIST criteria in patients with advanced lung cancer treated with nivolumab.
    Singla R; Jajodia A; Agrawal RK; Rao A; Pasricha S; Batra U
    J Cancer Res Ther; 2023; 19(5):1212-1218. PubMed ID: 37787285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. iRECIST: how to do it.
    Persigehl T; Lennartz S; Schwartz LH
    Cancer Imaging; 2020 Jan; 20(1):2. PubMed ID: 31900236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy.
    Vrankar M; Unk M
    Radiol Oncol; 2018 Oct; 52(4):365-369. PubMed ID: 30367809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. iRECIST and atypical patterns of response to immuno-oncology drugs.
    Ramon-Patino JL; Schmid S; Lau S; Seymour L; Gaudreau PO; Li JJN; Bradbury PA; Calvo E
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35715004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
    Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C
    Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST.
    Inno A; Lo Russo G; Salgarello M; Corrao G; Casolino R; Galli G; Modena A; Romano L; Pusceddu S; Greco FG; Garassino MC; Gori S
    Tumori; 2018; 104(2):88-95. PubMed ID: 29714647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy and the role of imaging.
    Carter BW; Bhosale PR; Yang WT
    Cancer; 2018 Jul; 124(14):2906-2922. PubMed ID: 29671876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in assessing solid tumor responses to immunotherapy.
    Chai LF; Prince E; Pillarisetty VG; Katz SC
    Cancer Gene Ther; 2020 Aug; 27(7-8):528-538. PubMed ID: 31822814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria.
    Vernuccio F; Godfrey D; Meyer M; Williamson HV; Salama JK; Niedzwiecki D; Stephens SJ; Ronald J; Palta M; Marin D
    AJR Am J Roentgenol; 2019 Dec; 213(6):1232-1239. PubMed ID: 31613663
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.